Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3022855 with BRAF/MEK Inhibition in Melanoma
NCT03101254Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2017
- Primary completion
- Oct 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LY3022855 in melanoma, sponsored by Dana-Farber Cancer Institute. Started Jun 2017; status: completed.
02
Drugs
LY3022855
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03101254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101254.